Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Cash from Financing Activities (2016 - 2025)

Standard Biotools (LAB) has disclosed Cash from Financing Activities for 16 consecutive years, with $620000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 101.14% to $620000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $570000.0 through Dec 2025, up 100.56% year-over-year, with the annual reading at $570000.0 for FY2025, 100.56% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $620000.0 at Standard Biotools, up from -$112000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $213.0 million in Q2 2022, with the low at -$54.5 million in Q4 2024.
  • Average Cash from Financing Activities over 5 years is $6.8 million, with a median of -$270000.0 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities soared 18474.29% in 2022, then tumbled 23180.0% in 2023.
  • Over 5 years, Cash from Financing Activities stood at $8.7 million in 2021, then tumbled by 103.12% to -$270000.0 in 2022, then tumbled by 271.48% to -$1.0 million in 2023, then crashed by 5335.69% to -$54.5 million in 2024, then soared by 101.14% to $620000.0 in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $620000.0, -$112000.0, and $108000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.